Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MERZEE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Short-term adjunctive therapy in the management of exogenous obesity,Off-label: weight loss maintenance
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 60 hours in severe impairment).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via N-demethylation and other oxidative pathways; metabolites include amphetamine and methamphetamine.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; biliary/fecal elimination accounts for about 25%, with the remainder as metabolites.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
98% bound to serum albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.15 L/kg, indicating limited extravascular distribution (primarily confined to plasma and interstitial fluid).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability: 45-55% (first-pass metabolism). Not applicable for intravenous route.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-89 m L/min: 300 mg twice daily; GFR <30 m L/min or on hemodialysis: 300 mg once daily.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A: no adjustment; Class B: 300 mg twice daily; Class C: not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for use in pediatric patients.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Consider lower initial dose (300 mg twice daily) due to age-related renal impairment; monitor for cognitive effects.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
MERZEE has a high potential for abuse and dependence. Use in patients with a history of drug abuse or alcoholism is not recommended. Administration for extended periods may lead to drug dependence and must be avoided.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of abuse and dependence; monitor for signs of abuse. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or anxiety states. Discontinue if tolerance develops. May impair ability to drive or operate machinery. Do not use with MAOIs or within 14 days of their discontinuation.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to benzphetamine or other sympathomimetics; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days of MAOI use; pregnancy; lactation.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
High-fat meals reduce peak concentration (Cmax) by 28% and delay time to peak concentration (Tmax) by 2 hours. Grapefruit juice may increase perampanel levels via CYP3A4 inhibition; consider monitoring for side effects if consumed regularly. Alcohol and CNS depressants (e.g., benzodiazepines, opioids) may potentiate dizziness and sedation.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimesters: no specific risk identified but limited data.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
No human data on excretion in breast milk; M/P ratio unknown. Risk to infant cannot be excluded. Use caution, considering importance of drug to mother.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No established dose adjustments due to lack of pharmacokinetic data in pregnancy. Clinical monitoring advised for efficacy and toxicity.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
MERZEE (perampanel) is a selective non-competitive AMPA receptor antagonist. Monitor for neuropsychiatric symptoms including hostility, aggression, and suicidal ideation, especially in patients with a history of psychiatric disorders. Due to its long half-life (~105 hours in steady state), dose adjustments should be made at intervals of at least 2 weeks. Avoid use in severe hepatic impairment (Child-Pugh C); dose reduction required for mild to moderate impairment. Contraception counseling is essential for women of childbearing potential as perampanel decreases efficacy of oral contraceptives containing levonorgestrel. Potent CYP3A4 inducers (e.g., carbamazepine, phenytoin) significantly reduce perampanel levels; consider dose adjustment.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not stop abruptly as this may increase seizure frequency.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects are known.,Report any changes in mood, behavior, or suicidal thoughts to your healthcare provider immediately.,Use effective non-hormonal contraception during treatment and for 1 month after stopping, as perampanel reduces efficacy of hormonal contraceptives.,Avoid alcohol and other CNS depressants as they can worsen side effects.,Do not take with high-fat meals as they delay absorption; take on an empty stomach or with a light meal.,Store at room temperature away from moisture and heat.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MERZEE vs ACTIQ, answered by our medical review team.
MERZEE is a Antihyperlipidemic (Cholesterol Absorption Inhibitor) that works by MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MERZEE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MERZEE is: 300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MERZEE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MERZEE is classified as Category C. Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimester. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.